Skip to content

Connectedness as a Mechanism of Change in Psilocybin-Assisted Cognitive Behavioral Therapy for Major Depressive Disorder

Lorenzo Miller, Cordelia Kuiper Rauch, Keren Chen, Nicholas J. Jackson, David J. Miklowitz, Marc J. Weintraub

Psychedelics October 1, 2026 DOI: 10.1016/j.psyche.2026.100044 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Open-label trial (secondary analysis) Randomized Peer reviewed
Sample size 15
Population Adults with major depressive disorder
Interventions Psilocybin cognitive behavioral therapy
Dose 10 mg, 25 mg
Duration 4-month treatment with 3-month post-treatment follow-up
Topics Depression Psilocybin
Key findings Connectedness increased significantly from baseline (M = 41.8) to post-treatment (M = 56.6; Hedges' g = 0.62) but was not sustained at three-month follow-up (M = 50.7). Increased connectedness predicted improved depressive and functioning outcomes at follow-up, and there was preliminary evidence that connectedness mediated the relationship between psychedelic effects and depressive symptom improvement.

Abstract

Background: Psilocybin-assisted therapy has shown robust antidepressant effects among individuals with major depressive disorder (MDD); however, mechanisms of the treatment remain unclear. Depression has been associated with diminished feelings of connectedness to oneself, others, and the world, and psilocybin is thought to facilitate connectedness. This analysis of an open-label trial of psilocybin-assisted cognitive behavioral therapy (PA-CBT) examined changes in connectedness over treatment and its associations with depressive symptoms and psychosocial functioning.

Methods: Adults with MDD were enrolled in PA-CBT, which included twelve psychotherapy sessions and two psilocybin sessions (10 mg, 25 mg) over 4 months and were followed for 3 months post-treatment. Linear mixed-effects models examined changes over time in feelings of connectedness and its associations with depressive symptoms and psychosocial functioning. Connectedness was also examined as a mediator in the relationship between psychedelic effects (mystical experiences and psychological insights) and depressive symptoms.

Results: Among fifteen participants, connectedness increased significantly from baseline (M = 41.8) to post-treatment (M = 56.6; Hedges' g = 0.62), but was not sustained at three-month follow-up (M = 50.7). Increased connectedness from baseline to post-treatment predicted improved depressive and functioning outcomes at follow-up, controlling for baseline scores. There was preliminary evidence of connectedness as a mediator between psychedelic effects and depressive symptom improvement.

Conclusion: This study provides preliminary evidence that feelings of connectedness may be a mechanism underlying psilocybin's benefits for individuals with MDD. Larger randomized controlled trials comparing psilocybin to other active control conditions are needed to clarify whether connectedness functions as a treatment-specific mechanism.

In the evidence

This study is part of the evidence base for 2 syntheses in the library. Here is how each one recorded it.

  • Connectedness rose significantly from baseline to post-treatment but was not sustained at 3 months, and greater increases predicted improved depressive and functioning outcomes at follow-up.

    Synthesized

  • Connectedness increased significantly from baseline to post-treatment (Hedges' g 0.62) and predicted improved depressive outcomes at follow-up, but the increase was not sustained at three months.

    Synthesized

Comparable studies

Other non-randomized and open-label trials on psilocybin for depression, most cited first.

Study Year Design Participants
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression 2016 Open-label feasibility trial n = 12
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression 2017 Open-label trial n = 20
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Patients with major depressive disorder 2021 Open-label study n = 24
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Individuals diagnosed with moderate to severe, treatment-resistant depression 2017 Open-label study n = 20

Citations in the library

Explore topics

By condition and practice